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Abstract 
Objective 
The decline of estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes 
is variable and early interventions would likely be cost effective. We elucidated the 
contribution of 17 plasma biomarkers to the prediction of eGFR loss on top of clinical risk 
factors. 
Research Design and Methods 
We studied participants in PROVALID, a prospective multinational cohort study of patients 
with type 2 diabetes and a follow up of more than 24 months (n = 2560; baseline median 
eGFR 84 mL/min/1.73m2, UACR 8.1 mg/g). The 17 biomarkers were measured at baseline 
in 481 samples using Luminex technology and ELISA. The prediction of eGFR decline was 
evaluated by linear mixed modeling. 
Results 
In univariable analyses nine of the 17 markers showed significant differences in median 
concentration between the two groups. A linear mixed model for eGFR obtained by variable 
selection exhibited an adjusted R2 of 62%. A panel of twelve biomarkers was selected by 
the procedure and accounted for 34% of the total explained variability, of which 32% were 
due to five markers. Each biomarker’s individual contribution to the prediction of eGFR 
decline on top of clinical predictors was generally low. When included into the model, 
baseline eGFR exhibited the largest explained variability of eGFR decline (R2 of 79%) and 
the contribution of each biomarker dropped below 1%. 
Conclusions 
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In this longitudinal study of patients with type 2 diabetes and maintained eGFR at baseline, 
12 of the 17 candidate biomarkers were associated with eGFR decline, but their predictive 
power was low. 
 
Keywords: diabetes, progression, biomarkers, chronic kidney disease, omics, 
systems biology, prognosis 
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Introduction 
The incidence of patients with type 2 diabetes is increasing worldwide and diabetic 
kidney disease (DKD) is a major cause of premature disability and death. Interventions 
in later stage chronic kidney disease (CKD) can only limit the damage and thus it is 
necessary to risk-stratify incident patients according to their projected disease course 
(1; 2). Unfortunately, the prediction of an individual’s loss of estimated glomerular 
filtration rate (eGFR) based on clinical and demographic parameters is poor (3). Thus, 
research in the last decade focused on the discovery of molecular markers for the 
refinement of individual CKD progression (4).  
Several candidate markers have been discovered that showed statistical associations 
with eGFR decline or progression of proteinuria (5). However, kidney disease in type 
2 diabetic patients is driven by a heterogeneous set of pathophysiological processes 
(6). Consequently, it is unlikely that a sole marker can capture all these different 
pathophysiological processes that lead to CKD progression. Thus investigators 
focused on parsimonious multi-marker panels. Such a molecular selection was derived 
and experimentally tested in the EU FP-7 project SysKid (Systems Biology toward 
Novel Chronic Kidney Disease Diagnosis and Treatment) (7). The biomarker panel 
added explained variability to a ‘clinical variable only’ model but has not yet been 
thoroughly validated in an independent cohort. In addition, several other prognostic 
biomarkers for kidney disease progression in patients with diabetes have been 
identified but were never validated as a combined marker panel in a specifically 
designed prospective cohort.  
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The aim of our study was to integrate high evidence biomarker candidates in a 
parsimonious panel of prognostic markers and to test their ability to predict eGFR loss 
when combined with commonly available clinical risk factors.  
The BEAt-DKD consortium (Biomarker Enterprise to Attack DKD; 
http://www.imi.europa.eu/projects-results/project-factsheets/beat-dkd) was founded to 
identify targetable mechanisms and pathways underlying initiation and progression of 
DKD, as well as to identify and validate biomarkers of disease progression and 
treatment responses. One of its first tasks is the validation of the best available 
biomarker candidates in a prospective cohort of patients with type 2 diabetes and early 
stage kidney disease. 
 
Research Design and Methods 
Biomarker Selection  
Biomarkers for the present study were selected from biomarker candidates generated 
by the SYSKID and SUMMIT consortia (8; 9). We integrated diverse sources of 
information relevant to the relationship with DKD including evidence from literature (4);  
transcriptomic analyses from microdissected renal tissue ascertained from subjects 
with DKD (www.nephroseq.org); whole blood methylation profiles from type 1 diabetic 
patients with and without DKD; and genetic association data. Priority biomarkers from 
this integration were assessed for availability of Luminex and ELISA assays and 
combined to maximize the number of markers that could be measured in a single 
sample aliquot. A listing of candidates from which the current 17 markers were selected 
is provided in supplement table 1. 
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Study Cohort and Selection of Study Participants   
The study cohort was derived from PROVALID, a prospective multinational cohort 
study of patients with type 2 diabetes and incident or early CKD (10-12). A flow chart 
of patient selection is provided in supplement figure 1. In total 4065 subjects were 
recruited in five countries. From those, 2560 subjects from Austria, Hungary and 
Scotland were available for this study. After excluding subjects with less than 720 days 
of follow up (FU), patients were grouped by CKD stage and broken up into quintiles 
based on their individual eGFR slopes (supplement table 2). PROVALID recruited 
subjects at the primary healthcare level and thus the number of patients in stages G4 
and G5 is low. For the remaining stages (G1 to G3b), samples in the fourth quintile 
(eGFR slope [-0.79, 1.39] ml/min/year) and first quintile (eGFR slope [-24.9, -5.2] 
ml/min/year) were deemed to be stable and fast progressors, respectively. Within the 
first quintile, stage G3 was underrepresented compared to the stable group and was 
therefore supplemented from the second quintile [-5.2, -2.58]. This selection yielded 
258 patients in the stable group (median eGFR slope 0.1 mL/min/year) and 223 
patients in the fast progressors group (median eGFR slope -6.75 mL/min/year). The 
two groups were closely matched for age, gender, BMI, blood pressure and baseline 
eGFR. Demographics of the study population and medication details are provided in 
table 1 and supplement table 3, respectively.   
Outcome of Interest 
The outcome of interest was renal function decline over time, which was determined 
annually by eGFR, estimated according to the CKD-EPI equation (13). 
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Clinical Risk Factors 
The following baseline clinical risk factors served as candidate predictors: age, gender, 
serum cholesterol, UACR, HbA1C, MAP and BMI. eGFR at baseline was either part of 
the dependent variable or included as predictor. Since anemia does not present a 
problem in early stage CKD, hemoglobin levels were omitted from the models.  
Biomarker Selection and Measurement  
All markers were measured in K3 EDTA plasma. A custom Human Premixed Multiplex 
Luminex (catalog no. CUST0I704; R&D Systems, Minneapolis, MN) was used to 
measure eleven markers with 1:2 sample dilution: Chitinase-3-like protein 1 (CHI3L1), 
Chemokine receptor ligand 2 (CCL2), Growth hormone (GH), Hepatocyte growth factor 
(HGF), Matrix metalloproteinase 1 (MMP1), Matrix metalloproteinase 7 (MMP7), Matrix 
metalloproteinase 8 (MMP8), Sclerostin (SOST), Tyrosine-Protein Kinase Receptor 
(TIE2), Tumor necrosis factor receptor 1 (TNFR1) and Vascular cell adhesion molecule 
1 (VCAM1). A second Human Premixed Multiplex Luminex Kit (catalog no. LXSAH-03; 
R&D Systems) was used to measure three markers with 1:50 sample dilution:  
Uromodulin (UMOD), Endostatin and Cystatin C. Samples were diluted using the 
calibrator diluent provided in the kit, processed according to manufacturer specification 
and measured on a Luminex 200 (Luminex Corporation, Austin, TX) with xPONENT 
software (version 3.1.971.0). Instrument settings were set according to assay protocol.  
For the calibration and verification of the Luminex a Luminex 200 Performance 
Verification Kit and Calibration Kit (catalog no 40-276 and 40-275, Merck Millipore, 
Billerica, MA) were used.  
Kidney injury molecule-1 (KIM1) was measured by ELISA (catalog no. DSKM100, R&D 
Systems). Samples were diluted 1:2, processed according to assay procedure and 
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measured on a TriStar² LB 942 Modular Multimode Microplate Reader (Berthold 
Technologies, Bad Wildbad, Germany) using wavelength settings as instructed in the 
assay procedure. Absolute concentrations were determined using MikroWin2010 
v5.21 software (Berthold Technologies). 
For quality control, Pooled Normal Human Plasma K3 EDTA (catalog no. IPLA-N-
100ml-K3 EDTA, Innovative Research, Novi, MI) was spiked with recombinant proteins 
(R&D Systems) to create low, medium and high-level controls.  
All samples were measured as two technical replicates and required to have a 
coefficient of variation (%CV) below 12%. In addition, 10% of all samples were 
remeasured on a different plate to perform FDA recommended incurred sample 
reanalysis. More than 72% of incurred sample reanalysis showed a percentage 
difference below 20% and measurements were therefore in concordance with FDA 
guidelines (supplement table 4). Values out of quantifiable range were set to 0.5 and 
1.5 times the lower and upper quantification limits, respectively (supplement table 5 
and supplement figure 2). 
Fibroblast growth factor 23 (FGF23) was measured using a FGF-23 (C-Term) ELISA 
(catalog no. 60-610, Quidel San Diego, CA) with a dilution of 1:2 according to 
manufacturer’s recommendations.  Signal was measured using EnVision plate reader 
(Perkin elmer, Waltham, MA) using optical density wavelength instructed by the 
procedure. N-terminal prohormone of brain natriuretic peptide (NTproBNP) was 
measured using an NTproBNP ELISA (catalog no. K151JKC, Mesoscale Discovery, 
Gaithersburg, MD) with a dilution of 1:10. Samples were processed according to 
manufacturer recommendations, and electrochemiluminescence signal was measured 
on a MESO QuickPlex SQ 120 (Mesoscale Discovery). Samples were measured in 
technical replicates. Interassay %CV was estimated using internal controls. Due to 
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limited available sample volume NTproBNP and FGF23 concentrations were 
determined in only 480 and 437 out of the 481 samples respectively and for 86 samples 
FGF23 concentration could only be determined in  single measurements. %CV were 
required to be less than 20% and average inter- and intra-assay %CV for FGF23 and 
NTproBNP were 5.5 and 3.2 and 13.2 and 7.0, respectively. 
Samples Size Estimate 
As all 17 biomarkers were pre-selected from previous projects, it was estimated that 
500 samples would be sufficient to reach more than 80% power to detect at least a 
single biomarker with a statistically significant effect on the outcome renal function 
decline (supplement figure 4). Key assumptions were derived from (7). 
Statistical Analysis 
Patient characteristics were described by mean and standard deviation, median and 
1st and 3rd quartile or frequency and percentage for continuous and binary variables, 
respectively. Biomarker levels between the stable and fast progressing patient groups 
were compared by means of Mann-Whitney U tests. To estimate the effects of clinical 
risk factors and protein biomarkers on the outcome we employed univariable and 
multivariable linear mixed models. eGFR baseline measurements take on a special 
role in such analysis as they can be understood as part of the outcome or as a clinical 
covariate. Our main goal was to validate the biomarkers as predictors for renal function 
decline; therefore, eGFR levels at baseline were considered as part of the outcome 
and thus included in the dependent variable as they are subject to the same random 
variation as later values. To compare the contribution of biomarkers and baseline 
eGFR to the prediction of future eGFR levels we repeated the same modeling 
procedure as described in the following but added baseline eGFR to the set of 
covariates and removed it from the dependent variable. Random intercepts and 
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random slopes were used to model the patient specific eGFR trajectories, imposing no 
restrictions on their covariance. Interaction terms with time were included to model the 
effect on the eGFR slope.  
Results are reported as coefficients and associated p-values. The baseline coefficient 
(main effect) can be interpreted as association with mean eGFR levels; the slope 
coefficient (interaction effect) as association with the eGFR change over time. We 
investigated the importance of predictors by applying backward elimination based on 
Akaike’s Information Criterion (AIC) on a model containing all protein biomarkers and 
clinical predictors. Hierarchy of interactions and main effects were kept intact: a 
baseline effect was only dropped if no associated slope effect was present in the 
model.  
The adjusted R2 of the fixed effects part was obtained by multiplying the unadjusted R2 
with a correction factor of (N-K-1)/(N-1), where N and K denote the number of patients 
and the number of fixed effects in the model, respectively. To further assess the 
contribution of specific covariates to the prediction of the outcome, we decomposed 
the adjusted R² by computing the drop in R² when excluding a specific covariate from 
the model, scaling the resulting values to add up to the total adjusted model R2.  
Biomarker levels were log2 transformed to normalize their distributions. The model 
results presented here were pooled by Rubin’s rules from multiply imputed datasets to 
account for uncertainty due to missing data in predictors. Thus, in each model all 481 
samples were included. By applying the variable selection procedure to each 
imputation we obtained selection frequencies facilitating assessment of model 
instability due to missing data. Our final model comprised predictors chosen in at least 
half of the imputations. Model instability due to general sampling variation was 
assessed by drawing bootstrap resamples in each imputed dataset.  
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Complete-case only analyses, the number of available samples per predictor and a 
description of the multiple imputation procedure is provided in the supplementary 
material.  
Logistic regression models were applied to obtain classification models for progression 
status based on the predictor values. 
P-values less than 0.05 were considered statistically significant and all p-values are 
two-sided. We used the R statistical software (https://www.r-project.org/foundation, 
Vienna, AT) for all analyses. 
 
Results  
In total, 481 patient baseline plasma samples were measured for 17 biomarkers. A 
detailed breakdown of availability by marker is provided in supplement table 6. Figure 
1 shows biomarker levels grouped by speed of progression of renal function decline. 
When comparing median levels using Mann-Whitney U tests, several markers showed 
a significant difference between the two groups of patients (no adjustment for multiple 
testing). However, the marker level distributions overlap and the observed differences 
are small with an average of 25%. Non-parametric Spearman correlation coefficients 
between biomarkers and clinical data are visualized as heatmap in supplement figure 
3. 
Supplement table 7 shows the results from univariable mixed model analysis. Reported 
baseline coefficients correspond to the prediction of mean eGFR levels at timepoint 
zero; slope coefficients to the prediction of the change of eGFR levels over time. 
Except for SOST, MMP8 and CCL2, all markers show a significant association with 
eGFR levels via the baseline coefficients. Most of these associations remain 
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significant, even after adjustment for clinical risk factors (supplement table 8). Only few 
biomarkers show a significant association with eGFR change over time via their slope 
coefficients.  
MMP8 (66% of samples below limit of quantification) and SOST (30% missing) were 
removed from all further multivariable analyses due to the high number of missing 
values and no apparent association with eGFR decline in univariable analysis. The 
results from the final model obtained from backward elimination are reported in table 
2. Overall the biomarker predictors account for 34.4% of the explained variability of 
eGFR levels. According to their contribution to explained variability, the biomarkers can 
be split into two groups (supplement table 9). Biomarkers in the first group are mainly 
useful for prediction of mean eGFR values via their baseline coefficients; their effect 
stays constant over time. The second group also adds to the prediction of eGFR 
change over time via their slope coefficients. However, the contribution of the second 
group to the model R² is comparatively small (30.9% and 3.5% for group one and two, 
respectively) indicating that the biomarkers contribute primarily through the prediction 
of mean eGFR levels. Figure 2 shows the model fit via predicted median eGFR 
trajectories for stable and fast progressing patients from the final mixed model together 
with observed eGFR distributions at each FU visit. An additional bootstrap procedure 
shows that almost all predictors from our final model are selected with high frequency, 
indicating satisfactory model stability (supplement table 10). Furthermore, multivariable 
models without variable selection including clinical covariates only and biomarkers on 
top of clinical covariates give an indication of the achievable predictive performance in 
this cohort (supplement tables 11 and 12). 
The weak association with eGFR slopes is further demonstrated by low discriminative 
power when using logistic regression models to discriminate between stable and fast 
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progressing patients. The resulting low Area Under the Curve (AUC) values 
corroborate our findings that the biomarkers are mainly associated with mean eGFR 
baseline levels (supplement table 13 and 14).  
Results from the analysis including baseline eGFR levels as covariate further indicate 
that the added value of the biomarkers on top of these measurements is low with 
regards to prediction of future eGFR levels. In corresponding univariable analyses, 
only six biomarkers remained significantly associated with mean eGFR levels, when 
baseline eGFR was included in the models (supplement table 15).  
The final model selected by backward elimination from the pool of candidate predictors 
including baseline eGFR is provided in supplement table 16. Compared to the model 
without baseline eGFR as covariate, further four biomarkers are eliminated from the 
model; otherwise biomarker selection remains similar (supplement table 17). The 
dominating influence of baseline eGFR levels on prediction of eGFR levels after 
baseline is expressed by their high adjusted R² measure, which is essentially equal to 
the model’s R² – dropping any other predictor leaves the model’s predictions virtually 
unchanged. However, even for baseline eGFR levels, the predictive power is mostly 
due to prediction of mean eGFR levels after baseline, rather than through the prediction 
of the eGFR slope. 
Corresponding complete-case only analyses and the number of available samples per 
predictor are provided in the supplement tables 18 and 19. The results remained 
largely unchanged with an adjusted R2 of 62% of the mixed model for eGFR prediction, 
thus supporting the validity of the results of the multiply imputed analysis. 
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Conclusions 
We performed a validation study of 17 pre-selected plasma protein markers with 
reported high evidence for the prediction of eGFR decline in patients with type 2 
diabetes and incident or early stage CKD. We showed that in an univariable analysis 
nine of the markers had significantly different concentration levels between patients 
with stable eGFR and fast progression of eGFR decline. Fourteen biomarkers 
significantly contributed to the prediction of eGFR levels. However, most of the 
predictive ability was attributable to the association with baseline GFR. In the 
multivariable analysis of eGFR decline over time only five markers (KIM1, FGF23, 
NTproBNP, HGF, MMP1) remained significant but exhibited only a modest predictive 
power on top of clinical covariates. Furthermore, if the longitudinal analysis was 
adjusted for baseline eGFR, none of the biomarkers were able to contribute a relevant 
portion of explained variability, suggesting that baseline eGFR is the key variable in 
prediction of renal function at a very early CKD stage. Interestingly urinary albumin 
excretion was only of limited value for predicting eGFR loss which may be explained 
by the minute amount of albuminuria in the patients investigated. 
 
Other studies of patients with type 2 diabetes and incident or early stage CKD have 
shown that even well-established clinical risk factors of later stage disease do not 
perform well in discriminating progressors at early stages. Dunkler and colleagues 
have shown by using only clinical variables that the discrimination for the progression 
of CKD in patients with type 2 diabetes is actually very low on an individual basis (14). 
eGFR and to some extent albuminuria were the most important factors for predicting 
progression but their predictive ability in total was modest.  
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Niewczas and colleagues showed that, on top of clinical covariates, elevated 
concentrations of serum TNFR1 in 410 patients with later stage disease and long term 
FU was strongly associated with baseline GFR and predicted ESRD that happened in 
59 patients after a median FU of twelve years (15). This is in line with our current and 
previous findings that TNFR1 exhibited the highest explained variability in the 
longitudinal analysis for eGFR loss. However, death as a competing risk factor in 
analysis of the progression of kidney disease needs to be considered here. It is 
possible that differences in lead-time bias between studies explain the discrepancies 
in biomarker prediction of eGFR decline between the present and other studies (15). 
For example, patients that reached ESRD in the Niewczas study exhibited 
macroalbuminuria of 623 µg/min already at baseline compared to very low grade 
albuminuria of 20 µg/min in patients without progression. Additionally, supporting the 
argument of a lead-time is the fact that patients who progressed to ESRD over 12 years 
exhibited an eGFR reduction by almost half to 61 mL/min/1.73m2 at baseline compared 
to non-progressors.  
 
A multinational consortium from France investigated serum TNFR1 as predictor of 
eGFR slope in 522 patients (median FU of four years) with type 2 diabetes at later CKD 
stages, i.e. albuminuria of more than 30 mg/mmol creatinine (16). The investigators 
applied logistic regression and found a statistically significant increase of ESRD 
discrimination in each TNFR1 baseline quartile, but parameter estimates for a 
multivariable model with clinical covariates were missing.  
 
Similar as in our previous study and in Saulnier et al. we used linear mixed models to 
separate the marker contributions into association with baseline eGFR and eGFR 
change over time (17). Our finding of higher levels of TNFR1 and NTproBNP in the fast 
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progressor group are in line with the association with renal function loss observed by 
Saulnier et al.   
 
Ban and colleagues reported serum MMP7 association with proteinuria and GFR in a 
cross-sectional analysis (18).  
 
In 2017, a group from Denver investigated the test characteristics of selected plasma 
biomarkers for predicting eGFR below 60 mL/min/year and albuminuria above 30 mg/g 
creatinine in patients with type 1 diabetes using principal component analysis and Cox 
proportional-hazards models (19). The main finding was that after adjustment for 
traditional risk factors only KIM1 and Cystatin C exhibited a significant but modest 
improvement in discrimination. The principal component holding the most promising 
markers increased the AUC by only two percent. These results are well in line with our 
finding that in patients with type 2 diabetes candidate biomarkers may not be useful for 
eGFR slope prediction. 
 
Recently, Garlo et al. observed results similar to our findings in their biomarker 
evaluation in over 5000 enrolled patients with type 2 diabetes (20). eGFR decline 
occurred in 98 patients over a median of 1.5 years. Established markers such as 
Cystatin C or biomarkers of tubular injury did not substantially improve the prediction 
of eGFR loss on top of clinical predictors. 
 
Our previous analysis of nine biomarkers in two cohorts of patients with different 
baseline eGFR showed that explained variability of eGFR loss in patients with eGFR 
below 60 mL/min was mainly driven by MMP7 and TNFR1 (7). In patients with baseline 
eGFR above 60 mL/min contribution of all markers was modest with an adjusted R2 of 
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15% and 35% for a combination of biomarkers and clinical predictors.  The inclusion 
of further eight well investigated biomarkers did not substantially increase the 
predictability of eGFR loss in our current analysis. However, the fact that nine out of 
the 17 markers showed statistically significant differences in concentration levels 
between the group of patients with stable kidney function and the group with fast renal 
function decline supports the initial marker selection for this study. Yet, our analysis 
showed that the main contribution of these biomarkers is their association with baseline 
eGFR values rather than eGFR slopes.  
 
The individual slope of eGFR loss is highly variable in patients with diabetes and may 
be modified by medication. However, the aim of the present study was to predict the 
slope from baseline biomarkers independently of subsequent interventions such as 
comedication, lifestyle changes or any other factors. Therefore, we did not use 
medication in our main model on purpose, because it would be a baseline-adjustment 
for interventions that occurred afterwards, hence using information not available at time 
of prediction. In addition, all patients in the PROVALID study were optimally treated 
according to guidelines for patients with diabetes (21; 22). An analysis including 
treatment status at baseline, corroborating the negligible effect of medication on the 
performance of the biomarkers can be found in supplement tables 20 and 21. 
 
A key strength of PROVALID is that the study was specifically designed for the 
validation of biomarkers in patients with type 2 diabetes (10). However, our study has 
a few limitations. The selection of patients from the PROVALID cohort was based on 
the outcome of eGFR. While this likely leads to over-optimistic results, our rationale 
was to maximize power to validate the candidate biomarkers utility to predict eGFR 
loss independently of clinical parameters. Since it turned out that even with the 
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preselection marker performance was poor in this cohort of early stage CKD patients 
this limitation is irrelevant. A potential limitation is the relative short FU of three years. 
However, all patients had baseline and annual eGFR determinations which led to a 
robust slope estimation and thus stable marker performance estimates.   
 
The strengths of our study are the careful analysis of biomarkers according to EMA 
and FDA standards in a multinational prospective study (http://academy.gmp-
compliance.org/guidemgr/files/UCM368107.PDF).  Sample aliquots were stored at 
minus 80°C immediately after collection and never thawed until analysis. The 
percentage difference between reruns was well within the FDA recommended range. 
A further asset is the thorough statistical analysis in which we dissociated the effects 
of markers on the prediction of baseline eGFR and slope alone and in combination with 
clinical covariates known to be key risk factors for CKD progression.  
 
In conclusion, the prediction of eGFR slope using baseline circulating biomarkers in 
combination with clinical parameters was modest. Most of the predictive power was 
generated by the association of markers with baseline eGFR, which was by far the 
strongest predictor of future eGFR levels. Given the inferior performance of this highly 
selected biomarker set in early stage CKD patients to predict future eGFR loss, it is 
unlikely that these markers will be useful for clinical decision making. Nevertheless, 
their assessment might be useful to identify individual biological processes that may 
contribute to the progression of very early stage renal disease. 
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Figure 1. Concentration levels (log2 transformed) for all 17 biomarkers grouped by 
speed of progression of renal function decline. All concentrations are given in pg/ml 
except for FGF23 which is given in relative units. Quantifiable range of assays is 
indicated by areas shaded in grey. Biomarkers marked with an * show a significant 
difference in median levels between the two groups (Mann-Whitney U test, no p-
value adjustment for multiple testing). 
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Figure 2. Predicted median eGFR trajectories from the multivariable linear mixed 
model for eGFR levels (with baseline eGFR as part of the dependent variable) 
obtained by AIC-based backward elimination (solid line). Shaded areas indicate the 
interquartile range of predictions. Superimposed boxplots show the observed values 
summarized at each yearly FU visit. 
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Table 1. Baseline characteristics of the study cohort, overall and stratified by stable or 
fast progression of eGFR decline. Data are reported as mean ± standard deviation, 
median (1st quartile, 3rd quartile) and absolute frequency (relative frequency) where 
appropriate. Supplement table 3 gives more details on medication of the study patients. 
None of the differences between the two groups are significant after adjusting for 
multiple comparisons by Holm’s method (except for eGFR decline, which is the 
outcome of the study). We compared medians of continuous variables with Mann-
Whitney U tests and proportions of categorical variables with Chi-squared tests.  
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  Baseline value 
 Missing Overall Stable Fast 
Number of patients  481 258 223 
Age (Years) 0 64 ± 9.3 64 ± 10 65 ± 9 
Gender (Female) 0 232 (47%) 117 (45%) 115 (50%) 
Smoking status (Never) 0 250 (51%) 134 (52%) 116 (50%) 
Duration of diabetes 
(Years) 
0 10.8 ± 8.8 10 ± 8 12 ± 9 
BMI (kg/m2) 0 31 ± 5.5 31 ± 5 32 ± 6 
Systolic blood pressure 
(mmHg) 
0 138 ± 17.4 138 ± 16 139 ± 19 
Diastolic blood pressure 
(mmHg) 
0 79 ± 10.3 79 ± 10 79 ± 10 
HbA1c (%; mmol/mol) 4 (<1%) 
6.8 (6.3 / 
7.6);51 (45 / 60) 
6.8 (6.3 / 7.7); 51 
(45 / 61) 
6.8 (6.2 / 7.6); 51 
(44 / 60) 
Hemoglobin (mmol/l) 9 (1%) 8.6 (8.1 / 9.3) 8.8 (8.2 / 9.3) 8.5 (7.9 / 9.1) 
Serum glucose (mmol/l) 1 (<1%) 7.4 (6.2 / 9) 7.5 (6.3 / 9) 7.4 (6 / 8.9) 
Serum cholesterol 
(mmol/l) 
1 (<1%) 4.6 (4 / 5.5) 4.6 (4 / 5.4) 4.6 (4 / 5.6) 
Serum creatinine 
(µmol/l) 
0 77 (66 / 95) 77 (67 / 95) 77 (65 / 95) 
UACR* (mg/g) 14 (3%) 8.8 (4.7 / 26.5) 8.2 (4.6 / 21) 9.2 (5 / 36.5) 
Glucose lowering 
agents† 
0    
None  59 (12%) 35 (14%) 24 (11%) 
1 – 2 agents  355 (74%) 192 (74%) 163 (73%) 
> 2 agents  67 (14%) 31 (12%) 36 (16%) 
Blood pressure lowering 
agents‡ 
0    
None  77 (16%) 52 (20%) 25 (11%) 
1 – 2 agents   195 (41%) 106 (41%) 89 (40%) 
> 2 agents  209 (43%) 100 (39%) 109 (49%) 
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  Baseline value 
 Missing Overall Stable Fast 
ESA therapy§ 0 11 (2%) 4 (2%) 7 (3%) 
eGFR CKD-EPI 
(ml/min/1.73m2) 
0 84 (64 / 94) 85 (65 / 96) 82 (63 / 94) 
eGFR CKD-EPI decline 
per year 
(ml/min/1.73m2/year) 
0 -0.71 (-6.3 / 0.2) 0.14 (-0.44 / 0.68) 
-6.75 (-9.04 / -
5.48) 
 
*UACR: Urinary albumin to creatinine ratio 
† Agent classes: Biguanides, Insulin, Sulfonylureas, DPPIV inhibitors/GLP1 agonists, 
Glinides, Glitazones, Alpha-Glucosidase-inhibitors, SGLT2 
‡ Agent classes: ACE inhibitors / ARBs, β-blockers, Calcium antagonists (including 
direct vasodilators), α-blockers, Diuretics (Thiazide diuretics / Loop diuretics) 
§ Including Darbepoetin alfa, Epoetin alfa, Epoetin beta, Epoetin theta, Epoetin zeta, 
Others 
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Table 2. Multivariable linear mixed model for prediction of eGFR levels (with baseline 
eGFR as part of the dependent variable) obtained from AIC-based backward 
elimination on all candidate predictors (log2 transformed biomarker and clinical). The 
model had an adjusted R² of 62.5%. Biomarkers had a total contribution of 34.4%, 
clinical risk factors had a total contribution of 28.1%. The decomposition of the model 
R² combines the contributions of baseline and slope coefficients for each predictor. 
 Baseline  Slope  
Predictor Coefficient p-
value 
Coefficient p-
value 
R² 
decomposition 
Constant 407.630 <0.001 -2.102 0.396 - 
Cystatin C -11.661 <0.001 n.s. n.s. 9 
Endostatin -2.957 0.133 n.s. n.s. <1 
UMOD 2.977 <0.001 n.s. n.s. 4.3 
CHI3L1 1.124 0.037 n.s. n.s. <1 
HGF 0.047 0.949 0.463 0.044 <1 
MMP1 0.731 0.187 -0.307 0.082 <1 
MMP7 -1.233 0.064 n.s. n.s. <1 
TIE2 4.622 <0.001 n.s. n.s. 3.3 
TNFR1 -10.888 <0.001 n.s. n.s. 12.9 
KIM1 -0.064 0.922 -1.084 <0.001 3 
FGF23 -0.983 0.269 0.456 0.086 <1 
NTproBNP 0.071 0.793 -0.253 0.006 <1 
Age (Years) -0.684 <0.001 0.048 0.039 27 
Current or former 
smoker 
2.460 0.024 n.s. n.s. <1 
MAP 0.085 0.087 n.s. n.s. <1 
Total cholesterol -0.762 0.096 n.s. n.s. <1 
n.s.: not selected 
